31 Jan, 2024 08:25 AM
Highlights:
-- icetana has received a US$168,000 (~AUD$250,000), five year order for its AI software solution from Canadian reseller Delco Security.
-- This is the expansion of an existing contrac...read more
30 Jan, 2024 08:32 AM
-- Excellent clinical data reported from TACTI-002 Phase II trial, including median Overall Survival of 35.5 months in first line non-small cell lung cancer (1L NSCLC) patients expressing PD-L1 (TPS...read more
29 Jan, 2024 08:18 AM
Highlights:
-- icetana has received a S$864,000 (~AUD$980,000), three year order for its AI software solution from Prosegur Singapore.
-- Deployment (programmed for Q3 FY24) will see the existin...read more
04 Jan, 2024 09:17 AM
SYDNEY, AUSTRALIA – 04 January 2024 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing nove...read more
22 Dec, 2023 03:16 PM
SYDNEY, AUSTRALIA – 22 December 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), advises that its registered office and principal plac...read more
21 Dec, 2023 12:12 PM
SYDNEY, AUSTRALIA – December 21, 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developi...read more
07 Dec, 2023 09:32 AM
SYDNEY, AUSTRALIA – 7 December 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel LAG-3 related i...read more
22 Nov, 2023 12:31 PM
SYDNEY, AUSTRALIA – November 22, 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing no...read more
